• Alkermes plc has released its first-quarter 2026 results, reporting revenue of US$392.91 million versus US$306.51 million a year earlier, while shifting from net income of US$22.46 million to a net loss of US$66.48 million.
• The combination of higher sales and a move to basic and diluted loss per share of US$0.40 from prior-year earnings per share highlights the company’s current profitability pressures despite revenue growth.
• We’ll now examine how Alkermes’ higher quarterly revenue but swing to a net loss shapes its existing investment narrative and risk profile.

The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Alkermes Investment Narrative Recap

To own Alkermes, you need to believe its psychiatry and sleep-disorder portfolio can justify continued investment despite near term earnings volatility. The Q1 2026 result, with higher revenue but a net loss, underscores that rising costs and R&D spend remain the key short term tension, while the most immediate risk is that ongoing profitability pressure could make those pipeline bets feel less comfortable if they extend longer than expected.

The recent update on alixorexton, including Vibrance-1 data and the launch of Brilliance Phase 3 studies, feels especially relevant against this earnings backdrop. That program now sits at the center of Alkermes’ pipeline story, and the company’s willingness to push into multiple late stage trials helps explain why reported revenue growth in Q1 is not yet flowing through to the bottom line.

Yet this revenue growth alongside a swing to losses also raises questions investors should be aware of about how long Alkermes can absorb elevated R&D spend if...

Alkermes' narrative projects $2.1 billion revenue and $238.9 million earnings by 2029. This requires 11.8% yearly revenue growth and a $2.8 million earnings decrease from $241.7 million today.

Uncover how Alkermes' forecasts yield a $44.24 fair value, a 29% upside to its current price.

Exploring Other Perspectives

Before this quarter, the most optimistic analysts were penciling in revenue of about US$2.5 billion and earnings of roughly US$717 million by 2029, which is a far more upbeat view than a risk narrative focused on heavy R&D and concentration in a few drugs, and Q1’s move into loss making territory may prompt you to reassess which story feels closer to reality.

Explore 5 other fair value estimates on Alkermes - why the stock might be worth just $38.20!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Alkermes research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Alkermes research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alkermes' overall financial health at a glance.

Searching For A Fresh Perspective?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 48 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.